Serum Steroid and Sex Hormone-Binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial
Alan R. Kristal(Fred Hutch Cancer Center), Ian M. Thompson(The University of Texas at San Antonio Health Science Center), Jeannette M. Schenk(Fred Hutch Cancer Center), Marian L. Neuhouser(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Frank Z. Stanczyk(University of Southern California), Kathryn B. Arnold(Fred Hutch Cancer Center), Phyllis J. Goodman(Translational Research Institute), YoonJu Song(The Catholic University of Korea Bucheon St. Mary's Hospital), Daniel Lin(University of Washington)
Cited by 82
Related Papers
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
|Nature Genetics|2018|1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568